ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ralph J. Damiano, Jr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jayawant, A. M.
Right arrow Articles by Damiano, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayawant, A. M.
Right arrow Articles by Damiano, R. J., Jr

Ann Thorac Surg 1999;67:618-623
© 1999 The Society of Thoracic Surgeons


Original Articles

2,3-Butanedione monoxime cardioplegia: advantages over hyperkalemia in blood-perfused isolated hearts

A. Mark Jayawant, MDa, Edward R. Stephenson, Jr, MDa, Ralph J. Damiano, Jr, MDa

a Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA

Accepted for publication July 23, 1998.

Address reprint requests to Dr Damiano, Section of Cardiovascular Surgery, Milton S. Hershey Medical Center, Pennsylvania State-Geisinger Health System, PO Box 850, Hershey, PA 17033
e-mail: rdamiano{at}psghs.edu


    Abstract
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Background. 2,3-Butanedione monoxime (BDM) has been shown to possess cardioprotective properties related to the inhibition of cross-bridge force development, the reduction of myofilament Ca2+ sensitivity, and the attenuation of intracellular Ca2+ transients. This study tested the hypothesis that cardiac arrest achieved with BDM would be as effective as that achieved with St. Thomas’ solution (StT).

Methods. Isolated rabbit hearts, studied on a blood-perfused Langendorff column, underwent 1 hour of ischemia (37°C) and 30 minutes of reperfusion. Cardioplegia was administered every 20 minutes in the form of (1) Krebs-Henseleit solution only (control), (2) 20 mmol/L of BDM, or (3) StT. Recovery of developed pressure, atrioventricular activation times, and tissue water content were measured.

Results. Recovery of developed pressure for the control, BDM, and StT groups was 44% ± 3% (p < 0.05 versus BDM and StT), 57% ± 5%, and 62% ± 4%, respectively. Atrioventricular activation times were significantly prolonged in the control group (42 ± 15 ms, p = 0.042) and the StT group (26 ± 9 ms, p = 0.034), but not in the BDM group (14 ± 8 ms). Tissue water content after reperfusion was 80% ± 0.4%, 80% ± 0.2%, and 76% ± 1.0% (p < 0.05 versus control) in the control, StT, and BDM groups, respectively.

Conclusions. 2,3-Butanedione monoxime was as effective as StT in protecting the myocardium. Unlike StT, BDM ameliorated myocardial edema and atrioventricular conduction delay after reperfusion.


    Introduction
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Hyperkalemic cardioplegia, although clinically efficacious, has fundamental shortcomings. Many of these deficiencies have been attributed to disturbances in calcium homeostasis. Membrane depolarization caused by extracellular high-potassium solutions results in cyclical opening and closing of voltage-sensitive sodium channels [1]. This steady-state inward sodium current promotes sodium-calcium exchange, which, along with calcium leak from the sarcoplasmic reticulum, contributes to intracellular calcium overload [2, 3]. The altered cellular environment provokes compensatory metabolic processes, notably the activation of sodium and calcium ion pumps, which expend energy in the ischemic cell [24]. In addition, cell swelling occurs as water is drawn into the myocyte from the hypotonic extracellular environment in response to intracellular potassium and chloride ion accumulation as well as sodium and calcium influx [1]. The clinical manifestations of such processes include myocardial stunning, arrhythmias, and myocardial edema [57]. The relation between these physiologic derangements and abnormal calcium ion homeostasis formed the basis of our hypothesis that an effective cardioplegic agent should result in pharmacologic attenuation of intracellular calcium ion interactions.

2,3-Butanedione monoxime (BDM), a cholinesterase activator, has been shown to possess cardioprotective properties related to the inhibition of cross-bridge force development, the reduction of myofilament Ca2+ sensitivity, and the attenuation of intracellular Ca2+ transients [811]. In isolated, crystalloid-perfused hearts and cardiomyocytes, BDM reduced myocardial ischemic damage when administered before, during, and after transient ischemia [1215]. However, the efficacy of BDM as a cardioplegic agent during global ischemia has not been examined in the intact, blood-perfused heart. This study tested the hypothesis that cardiac arrest achieved with BDM in a more clinically relevant, blood-perfused model would be as effective as that achieved with the most widely used traditional hyperkalemic cardioplegia, St. Thomas’ solution (StT).


    Material and methods
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Adult New Zealand white rabbits of either sex, weighing 2.8 to 4 kg, were used in this study. All animals received humane care in American Association for Accreditation of Laboratory Animal Care– (#00036) and U.S. Department of Agriculture–registered (#52-R-007) facilities in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (Publication No. 86-23, revised in 1985.)

Experimental preparation
Preparation of the support animal
The support animal was anesthetized intramuscularly with acepromazine (1 mg/kg) and xylazine (17.5 mg/kg), followed by ketamine (62.5 mg/kg). Anesthesia was monitored throughout the experiment and supplemented as needed. A tracheostomy was performed, an endotracheal tube inserted, and mechanical ventilation begun with 100% oxygen (ventilator Model 683; Harvard Apparatus, Dover, MA). Ventilator settings were adjusted to maintain arterial pH between 7.35 and 7.5, PCO2 between 35 and 45 mm Hg, and PO2 greater than 200 mm Hg.

Heparin (2,500 U) was given through an ear vein. The right femoral artery was cannulated and the cannula was connected to a pressure transducer (Model P231D; Gould Inc, Cleveland, OH) and monitored continuously on our recording system (Gould ES 1000; Gould Inc). A systolic blood pressure of greater than 80 mm Hg was maintained by the transfusion of either blood collected from the donor animal or Plasmalyte (Baxter Healthcare Corp, Deerfield, IL). Serial hematocrits were measured.

The left internal jugular vein and the left carotid artery were cannulated. The cannulas were attached to silicone elastomer tubing with an internal diameter of 0.125 inch (Baxter Scientific Products, McGaw Park, IL), which was positioned in roller pumps. Arterial blood was pumped (Masterflex Model 7013; Cole Parmer Instrument Co, Chicago, IL) to perfuse a modified Langendorff apparatus described previously [16]. Indomethacin (1 mg/kg) was administered to the support animal to augment blood pressure stability [16].

Preparation of the donor animal and isolated heart
The donor animal was anesthetized, intubated, ventilated, and heparinized as described earlier. A cardiectomy was accomplished rapidly through a median sternotomy. Blood for transfusion was collected from the thoracic cavity. The aorta was cannulated with the heart suspended from a modified Langendorff apparatus and blood perfusion was begun.

A fluid-filled latex balloon was placed into the left ventricle and secured with a pursestring suture in the mitral valve annulus. The balloon was connected by polyethylene tubing to a pressure transducer (Model P231D; Gould, Inc) and amplifier (Model 13-4615-50; Gould Inc). The zero-pressure reference was set at the level of the aortic valve. Two needle electrodes were secured in the right atrial appendage and connected to a pacemaker (Model 5320; Medtronic, Inc, Minneapolis, MN).

For the duration of the study, the heart rate was maintained at a constant rate of 180 to 240 beats/min. Two additional electrodes were placed on the left ventricular epicardium to monitor the bipolar ventricular electrogram. The electrodes were connected to an isolated preamplifier (Model 11-G5407-58; Gould Inc) and a universal amplifier (Model 13-4615-58; Gould Inc) and filtered between 0.05 and 1,000 Hz. The pressure and electrogram waveforms were displayed continuously and digitized in real time using an AT-CODAS system (DATAQ Instruments, Akron, OH) at a sampling rate of 1,000 Hz.

The heart was enclosed in a water-jacketed beaker, and myocardial temperature was monitored with a probe placed in the right ventricle (temperature probe Model 0112; Shiley Inc, Irvine, CA). Myocardial temperature was maintained at 37°C by adjusting the temperature of the water bath (Model 71; Polyscience, Niles, IL). At hourly intervals, heparin (500 U) was administered to the support animal.

Experimental protocol
Hearts that did not generate a systolic pressure of greater than 80 mm Hg at an end-diastolic pressure (EDP) of 10 mm Hg were excluded from the study. After instrumentation, the hearts were given 30 minutes to equilibrate and preischemic data were acquired. Intracavitary left ventricular pressure waveforms and left ventricular bipolar electrograms were recorded over seven balloon volumes, each corresponding with a fixed intracavitary EDP (0, 2.5, 5, 10, 15, 20, and 25 mm Hg).

The hearts were randomized to receive 50 mL of one of three cardioplegic solutions, every 20 minutes, beginning with the onset of 1 hour of normothermic, global ischemia: (1) no cardioplegia (Krebs-Henseleit solution only, control, n = 6); (2) StT (n = 6); or (3) BDM in Krebs-Henseleit solution (5 mmol/L, n = 6). Krebs-Henseleit solution consisted of 118.5 mmol/L of NaCl, 25 mmol/L of NaHCO3, 3.2 mmol/L of KCl, 1.2 mmol/L of MgSO4, 1.2 mmol/L of KH2PO4, 2.5 mmol/L of CaCl2, and 5.5 mmol/L of glucose. The dose of BDM used in this study was chosen on the basis of previous studies performed in our laboratory that documented reversible arrest in isolated myocyte preparations with the use of 5 mmol/L of BDM, as well as work by others that demonstrated myocardial protection in crystalloid-perfused hearts with the use of BDM in this dose range [12].

After 1 hour of normothermic, global ischemia, the hearts were reperfused for 30 minutes. Intracavitary left ventricular pressure waveforms and electrograms were recorded over the identical range of balloon volumes recorded during preischemic data acquisition. At the conclusion of the study, a sample of the left ventricle was excised, blotted, weighed, and dried until a constant dry weight was reached. Myocardial edema was expressed as the percentage of tissue water in the following equation:

Data analysis
Digitized pressure waveforms were collected on data files analyzed using software developed in our laboratory.

End-systolic pressure
The end-systolic pressure (ESP) of a beat was defined as the maximum point of the digitized pressure waveform as described previously [16]. The ESP versus balloon volume data were fitted to a linear ESP-V relation (ESPVR) with a least-squares linear regression:

where Emax is the slope of the ESPVR and k is the y-axis intercept of the ESPVR.

End-diastolic pressure
The EDP of a beat was defined as the point at which the slope of the pressure waveform exceeded 0.5 mm Hg/ms. The EDP versus balloon volume data were fitted to a linear EDP-V relation (EDPVR) with a least-squares linear regression:

where m is the slope of the EDPVR and V0 is the balloon volume at which EDP is zero, or the x-axis intercept. A linear representation of the EDPVR has been shown to be appropriate over the range of volumes examined in this model [16].

Developed pressure
Developed pressure in the left ventricle (DP) was defined as the difference between ESP and EDP for a given beat. The DP of 10 beats was averaged for each balloon volume. The DP versus balloon volume data were fitted to a linear pressure-volume relation using the following regression:

Recovery of developed pressure
The recovery of DP, expressed as a percentage, was calculated as the ratio of the postreperfusion developed pressure to the preischemia developed pressure at the same balloon volume. The average percent recovery of developed pressure (%DP) was determined from the following definite integral, approximated using the trapezoidal rule:

where Vb is the largest matching postreperfusion balloon volume and Va is the smallest matching postreperfusion balloon volume.

Statistical analysis
The results are expressed as the mean plus or minus the standard error of the mean. Analysis of variance was used for multiple comparisons. When appropriate, the Kruskal-Wallis analysis of variance on ranks was used as a nonparametric alternative. Individual comparisons between groups were made with a Student-Newman-Keuls posttest. A one-way repeated-measures analysis of variance was used for comparisons that involved sequential, time-based measurements. When appropriate, the Kruskal-Wallis analysis of variance on ranks was used as a nonparametric alternative. A t-test, or paired t-test when appropriate, was used for comparisons between two sets. Differences were considered statistically significant when p < 0.05.


    Results
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
There were no significant differences in PO2; PCO2; serum sodium, potassium, or calcium; or hematocrit in the support animal throughout the study. The pH of the support animal was maintained within the normal range (7.40 to 7.60) throughout the experiment.

Temporal aspects of the development of electromechanical arrest
The time required to achieve electrical arrest was significantly shorter in the StT group compared with both the control group and the BDM group (Table 1). However, there were no significant differences between StT and BDM in the time required to achieve mechanical arrest, which occurred more rapidly in both treatment groups compared with the control group.


View this table:
[in this window]
[in a new window]
 
Table 1. Electrical and Mechanical Activitya

 
Atrioventricular conduction times
The PR interval was significantly prolonged throughout the reperfusion period compared with preischemic values in the control and StT groups (Table 1). In contrast, no conduction delay was observed in the BDM group.

Postischemic systolic function
The infusion of both BDM and StT resulted in improved recovery compared with control solution (Fig 1). Recovery of developed pressure after reperfusion in the BDM group was statistically equivalent to that in the StT group.



View larger version (21K):
[in this window]
[in a new window]
 
Fig 1. Postreperfusion systolic function, as assessed by percent recovery of developed pressure (%DP). Results are expressed as means plus or minus standard error of the mean. *p < 0.05 versus control. (BDM = 2,3-butanedione monoxime; CONTROL = no cardioplegia; StT = St. Thomas’ solution.)

 
Postischemic diastolic compliance
Changes in diastolic compliance were measured using a fixed volume analysis. Before ischemia and after reperfusion, left ventricular EDP (LVEDP) was recorded at an identical balloon volume corresponding with a preischemic LVEDP of 5 mm Hg. The postreperfusion LVEDP in the control, BDM, and StT groups was 30.8 ± 12.2 mm Hg (p = 0.09 versus before ischemia), 4.0 ± 0.2 mm Hg (p = 0.01), and 4.3 ± 0.5 mm Hg (p = 0.23), respectively. No statistically significant loss of compliance was produced in any group, although the control group showed a trend toward decreased compliance. Compliance increased slightly in the BDM group.

Myocardial tissue water
Compared with the control group, the mean percentage of tissue water was significantly reduced only in the BDM group (Fig 2). There were no significant differences in tissue water content between control hearts and those that received StT.



View larger version (15K):
[in this window]
[in a new window]
 
Fig 2. Effect of no cardioplegia (CONTROL), St. Thomas’ solution (StT), and 2,3-butanedione monoxime (BDM) cardioplegia on postreperfusion myocardial tissue water content (%H2O). Results are expressed as means plus or minus standard error of the mean. *p < 0.05 versus control and StT.

 
Coronary flow
Compared with control and StT hearts, BDM-protected hearts showed a prolonged hyperemic state on reperfusion (Fig 3). All three groups demonstrated a return to preischemic coronary flows by the end of the reperfusion period.



View larger version (26K):
[in this window]
[in a new window]
 
Fig 3. Coronary blood flow (CBF) under preischemic conditions (time = 0 min) and effect of no cardioplegia (CONTROL), St. Thomas’ solution (ST. THOMAS’ SOLN), and 2,3-butanedione monoxime (BDM) cardioplegia on CBF during the reperfusion period (time = 60 to 90 min). Results are expressed as means plus or minus standard error of the mean. *p < 0.05 versus preischemic CBF.

 

    Comment
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Cardioprotective effects of 2,3-butanedione monoxime
The ideal cardioplegic agent should be able to produce rapid mechanical arrest while maintaining the myocyte in a state of minimal metabolic demand. Previous observations have suggested that BDM may be an attractive alternative to traditional cardioplegia [915]. 2,3-Butanedione monoxime attenuates plasmalemmal and sarcolemmal calcium flux, possibly through dephosphorylation of calcium channels [10]. Further, BDM also directly interferes with actin-myosin cross-bridge force production [10, 11], which appears to be its dominant mechanism of negative inotropy.

Although BDM has been shown to be cardioprotective during ischemia, it has not been tested as a cardioplegic agent in a clinically relevant, intact, blood-perfused heart model. This study demonstrated that BDM is as effective a cardioplegic agent as traditional StT in a more clinically relevant, blood-perfused model. The infusion of either BDM or StT solution resulted in improved postischemic recovery of systolic function compared with the infusion of control solution (Fig 1), and both solutions preserved the preischemic diastolic properties.

Induction of electromechanical arrest with 2,3-butanedione monoxime
Traditional cardioplegic solutions have been designed to induce rapid electromechanical arrest to minimize energy consumption during the period of global ischemia. In this study, BDM demonstrated an ability to mechanically arrest the heart as quickly as potassium cardioplegia (Table 1). The time required to achieve mechanical arrest in the BDM and StT groups was significantly lower than that in the unprotected, control group.

Electrical arrest times were significantly prolonged with BDM compared with StT cardioplegia, but this did not influence the agents’ cardioprotective capabilities. Previous work in our laboratory has shown that as long as there is rapid mechanical arrest, persistent electrical activity does not adversely affect functional recovery and does not result in measurable high-energy nucleotide depletion after ischemia [17]. This is due to the fact that the amount of oxygen needed to maintain electrical activity comprises less than 1% of the total basal oxygen consumption of the heart [17].

Myocardial edema
Unlike StT, BDM cardioplegia ameliorated postreperfusion myocardial edema (Fig 2). Myocardial edema has been implicated in many of the contractile, metabolic, and electrophysiologic disturbances that occur after surgical ischemia. Cell swelling depresses left ventricular performance, results in delayed and abnormal ventricular conduction, and decreases coronary perfusion [2, 7, 18]. Moreover, intracellular volume appears to be a crucial second messenger in the regulation of cellular metabolism, hormone and transmitter release, ion transport, and even such complex functions as cell proliferation and apoptosis [19]. The ability of BDM to reduce myocardial edema may be related to its ability to attenuate transmembrane calcium flux and, subsequently, intracellular ion accumulation [10].

Coronary blood flow
In the StT group, the initial reperfusion hyperemia dropped to preischemic values almost immediately. In the BDM cardioplegia group, reperfusion flow remained elevated from preischemic values for 5 minutes (Fig 3). By the end of the reperfusion period, flows in both groups were similar to preischemic levels. One possible explanation for this finding is that BDM is a known coronary vasodilatory agent [12]. In the immediate reperfusion period, this effect may allow for better washout of toxic metabolites and better delivery of oxygen and substrates. An additional mechanism to explain BDM’s prolonged hyperemia may be related to its amelioration of postischemic myocardial edema, which has been associated with decreased coronary perfusion [20].

Atrioventricular conduction
Our laboratory and others have shown that cell swelling and edema is associated with slowed ventricular conduction [2, 7, 21]. In this study, delays in atrioventricular conduction, as evidenced by significantly prolonged postischemic PR intervals, were observed in the control and StT groups (Fig 3). In contrast, no significant conduction delays were observed in the BDM group.

Previous work in our laboratory demonstrated significant delays in ventricular activation with the use of standard hyperkalemic solutions [21]. These studies suggested that the injury produced by crystalloid cardioplegia did not involve active membrane properties, but involved intracellular edema, which decreased the extracellular space, resulting in a higher resistance to current flow [21]. The findings in this study are consistent with this hypothesis. Postischemic edema was significantly less severe in the BDM group than in either the control group or the StT group. This implicates edema as playing an important role in postischemic conduction delays.

Advantages and disadvantages of the blood-perfused isolated heart langendorff model
The advantages and drawbacks of the blood-perfused isolated heart Langendorff model have been described previously [16]. The use of a support animal can introduce variability related to ionic and hormonal fluctuations. However, continuous, careful monitoring yields a stable and reproducible preparation. The more physiologic nature of this model is a distinct advantage over nonparabiotic and crystalloid-perfused models.

Summary
This study demonstrated that BDM cardioplegia is as effective as conventional StT in protecting the myocardium from global ischemic injury in the blood-perfused isolated heart model. Unlike StT, BDM cardioplegia ameliorated postreperfusion myocardial edema and prevented delays in atrioventricular conduction, which have been implicated in postischemic arrhythmogenesis and ventricular dysfunction. 2,3-Butanedione monoxime may be an attractive alternative to traditional cardioplegia. In vivo studies are needed for further characterization of the clinical efficacy of this cardioplegic agent.


    References
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 

  1. Drewnowska K., Clemo H.F., Baumgarten C.M. Prevention of myocardial intracellular edema induced by St. Thomas’ Hospital cardioplegic solution. J Mol Cell Cardiol 1991;23:1215-1221.[Medline]
  2. Kleber A.G., Oetliker H. Cellular aspects of early contractile failure in ischemia. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., Morgan H.E., eds. The heart and cardiovascular system. New York: Raven, 1992:1975-1996.
  3. Reimer K.A., Jennings R.B. Myocardial ischemia, hypoxia and infarction. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., Morgan H.E., eds. The heart and cardiovascular system. New York: Raven, 1992:1875-1973.
  4. Blaustein M.P. Sodium/calcium exchange and the control of contractility in cardiac muscle and vascular smooth muscle. J Cardiovasc Pharmacol 1988;12(Suppl 5):S56-S68.
  5. Bolli R. Mechanism of myocardial stunning. Circulation 1990;82:723-728.[Abstract/Free Full Text]
  6. Gettes L.S., Cascio W.E. Effect of acute ischemia on cardiac electrophysiology. In: Fozzard H.A., Haber E., Jennings R.B., Katz A.M., Morgan H.E., eds. The heart and cardiovascular system. New York: Raven, 1992:2021-2054.
  7. Foglia R.P., Steed D.L., Follette D.M., DeLand E., Buckberg G.D. Iatrogenic myocardial edema with potassium cardioplegia. J Thorac Cardiovasc Surg 1979;78:217-222.[Abstract]
  8. Hebisch S., Bischoff E., Soboll S. Influence of 2,3-butanedione monoxime on heart energy metabolism. Basic Res Cardiol 1993;88:566-575.[Medline]
  9. Smith G.L., Steele D.S. Effects of 2,3-butanedione monoxime on sarcoplasmic reticulum of saponin-treated rat cardiac muscle. Am J Physiol 1993;265:H1493-H1500.[Abstract/Free Full Text]
  10. Gwathmey J.K., Hajjar R.J., Solaro R.J. Contractile deactivation and uncoupling of crossbridges: effects of 2,3-butanedione monoxime on mammalian myocardium. Circulation 1991;69:1280-1292.
  11. Perreault C.L., Mulieri L.A., Alpert N.R., Ransil B.J., Allen P.D., Morgan J.P. Cellular basis of negative inotropic effect of 2,3-butanedione monoxime in human myocardium. Am J Physiol 1992;263:H503-H510.[Abstract/Free Full Text]
  12. Boban M., Stowe D.F., Kampine J.P., Goldberg A.H., Bosnjak Z.J. Effects of 2,3-butanedione monoxime in isolated hearts: protection during reperfusion after global ischemia. J Thorac Cardiovasc Surg 1993;105:532-540.[Abstract]
  13. Elz J.S., Mayler W.G. Contractile activity and reperfusion-induced calcium gain after ischemia in the isolated rat heart. Lab Invest 1988;58:653-659.[Medline]
  14. Nayler W.G., Elz J.S., Buckley D.J. Dissociation of hypoxia-induced calcium gain and rise in resting tension in isolated rat hearts. Am J Physiol 1988;254:H678-H685.[Abstract/Free Full Text]
  15. Siegmund B., Klietz T., Schwartz P., Piper H.M. Temporary contractile blockade prevents hypercontracture in anoxic-reoxygenated cardiomyocytes. Am J Physiol 1991;260:H426-H435.[Abstract/Free Full Text]
  16. Lawton J., Sepic J., Allen C., Hsia P., Damiano R. Myocardial protection with potassium channel openers is as effective as St. Thomas’ solution in the rabbit heart. Ann Thorac Surg 1996;62:31-39.[Abstract/Free Full Text]
  17. Maskal S.L., Fields C.E., Cohen N.M., Damiano R.J. Persistent electrical activity during hyperpolarized cardiac arrest does not affect post ischemic myocardial recovery. Surg Forum 1995;46:222-224.
  18. Hus D., Weng Z., Nicolosi A.C., et al. Quantitative effects of myocardial edema on the left ventricular pressure-volume relation. J Thorac Cardiovasc Surg 1993;106:651-657.[Abstract]
  19. Lang F., Buisch G.L., Bolkl H., Haussinger D. Cell volume: a second message in regulation of cellular function. News in Physiological Sciences 1995;10:18-22.[Abstract/Free Full Text]
  20. Willerson J.T., Watson J.T., Hutton I., Templeton G.H., Fixler D.E. Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog. Circ Res 1975;36:771-781.[Abstract/Free Full Text]
  21. Cohen N.M., Allen C.A., Hsia P., Nixon T.E., Wise R.M., Damiano R.J. Electrophysiological consequences of hyperkalemic cardioplegia during surgical ischemia. Ann Thorac Surg 1994;57:1076-1083.[Abstract]



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. Borlak and C. Zwadlo
The Myosin ATPase Inhibitor 2,3-Butanedione monoxime Dictates Transcriptional Activation of Ion Channels and Ca2+-Handling Proteins
Mol. Pharmacol., September 1, 2004; 66(3): 708 - 717.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. Mukherjee, W. M. Yarbrough, E. S. Reese, J. S. Leiser, J. A. Sample, J. T. Mingoia, A. E. Hardin, R. E. Stroud, J. E. McLean, J. W. Hendrick, et al.
Myocyte contractility with caspase inhibition and simulated hyperkalemic cardioplegic arrest
Ann. Thorac. Surg., May 1, 2004; 77(5): 1684 - 1689.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
S. A. F. Tulner, R. J. M. Klautz, G. L. van Rijk-Zwikker, F. H. M. Engbers, J. J. Bax, J. Baan, E. E. van der Wall, R. A. Dion, and P. Steendijk
Perioperative Assessment of Left Ventricular Function by Pressure-Volume Loops Using the Conductance Catheter Method
Anesth. Analg., October 1, 2003; 97(4): 950 - 957.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. J. Chambers
Mechanisms and alternative methods of achieving cardiac arrest
Ann. Thorac. Surg., February 1, 2003; 75(2): S661 - 666.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
U. Mehlhorn, H. J. Geissler, G. A. Laine, and S. J. Allen
Myocardial fluid balance
Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1220 - 1230.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Ralph J. Damiano, Jr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jayawant, A. M.
Right arrow Articles by Damiano, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayawant, A. M.
Right arrow Articles by Damiano, R. J., Jr


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS